These inhibitors included GNE7883, a potent, reversible, allosteric inhibitor of the YAP1‐TEAD interaction [5], IAG933 that is currently in phase I clinical study in patients with mesothelioma, NF2/LATS1/LATS2‐mutated tumours and tumours with functional YAP1/TAZ fusions [11, 29] and VT107 currently being studied in clinical trials for its potential to inhibit TEAD auto‐palmitoylation in mesothelioma [30]. This evidence concerns the gene LATS2 and neoplasm.